Actinogen Medical Ltd has released a press release.
Strategic Update & Teleconference Call Notification
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen CEO assumes Managing Director position
- Actinogen appoints Dr Steven Gourlay as CEO
- ACW raises an addtional $3.55m under a Shortfall Placement
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
Later from Actinogen Medical
- Response to ASX Price Query
- Actinogen Ethics Committee approval for XanaMIA study
- Clinical progress for XanaMIA trial
- Actinogen receives positive Pre-IND FDA advice for FXS
- First Patient Enrolled in XanaMIA trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical